Revenue Update on pSivida Corp.(NASDAQ:PSDV)

pSivida Corp.(NASDAQ:PSDV) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-hours on Sep 12, 2016. Company reported revenue of $304.00K. Analysts estimated a revenue of $1.43M. Earnings per share were $-0.19. Analysts had estimated an EPS of $-0.13.

pSivida Corp. (PSDV) shares turned negative on Tuesdays trading session with the shares closing down -0.005 points or -0.14% at a volume of 74,915. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $3.51. The peak price level was also seen at $3.51 while the days lowest was $3.45. Finally the shares closed at $3.465. The 52-week high of the shares is $5.81 while the 52-week low is $2.37. According to the latest information available, the market cap of the company is $118 M.

Several Insider Transactions has been reported to the SEC. On Jan 5, 2016, Leonard S Ross (Vice President, Finance) sold 5,000 shares at $4.70 per share price.Also, On Dec 23, 2015, Paul Ashton (President & CEO) sold 120,000 shares at $5.39 per share price.

pSivida Corp. is a biotechnology company which is engaged in the development of sustained-release drug-delivery products for treating eye diseases. The Company offers products for treatment of back-of-the-eye diseases. The Company’s lead development product Medidur is used for posterior of the eye (posterior uveitis). Medidur is in Phase III clinical trials. The Company’s pre-clinical development program is focused on developing products using its platform technologies Durasert and Tethadur to deliver drugs and biologics to treat ophthalmic diseases such as wet and dry age-related macular degeneration (AMD) glaucoma and osteoarthritis among others. Its Durasert technology platform delivers therapeutics for predetermined periods of time ranging from days to years. Its Tethadur technology system utilizes BioSilicon nanostructured elemental silicon designed to provide sustained delivery of biologic molecules such as peptides proteins and antibodies.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

pSivida Corp. - Is it time to Sell?

Top Brokerage Firms are advising their investors on pSivida Corp.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.